This secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial estimates the long-term risk of any prostate cancer and clinically significant prostate cancer associated with baseline prostate-specific antigen (PSA) levels among men aged 55 to 60 years. This evidence concerns the gene KLK3 and prostate carcinoma.